A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder
Introduction The heterogeneity of symptoms and complex etiology of depression pose a
significant challenge to the personalization of treatment. Meanwhile, the current application …
significant challenge to the personalization of treatment. Meanwhile, the current application …
The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis
JD Rosenblat, Y Lee, RS McIntyre - Journal of affective disorders, 2018 - Elsevier
Background Pharmacogenomic testing has recently become scalable and available to guide
the treatment of major depressive disorder (MDD). The objective of the current meta-analysis …
the treatment of major depressive disorder (MDD). The objective of the current meta-analysis …
Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies
JD Rosenblat, Y Lee, RS McIntyre - The Journal of clinical …, 2017 - psychiatrist.com
Objective: Pharmacogenomic testing has become scalable and available to the general
public. Pharmacogenomics has shown promise for predicting antidepressant response and …
public. Pharmacogenomics has shown promise for predicting antidepressant response and …
Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools
CA Bousman, BW Dunlop - The Pharmacogenomics Journal, 2018 - nature.com
The degree of agreement between four commercial pharmacogenetic-based decision
support tools (DSTs) was examined in five outpatients with major depressive disorder and at …
support tools (DSTs) was examined in five outpatients with major depressive disorder and at …
Pharmacogenetics of antipsychotics
EJ Brandl, JL Kennedy… - The Canadian Journal of …, 2014 - journals.sagepub.com
Objective: During the past decades, increasing efforts have been invested in studies to
unravel the influence of genetic factors on antipsychotic (AP) dosage, treatment response …
unravel the influence of genetic factors on antipsychotic (AP) dosage, treatment response …
New‐generation, non‐SSRI antidepressants: Drug‐drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others
M Protti, R Mandrioli, C Marasca… - Medicinal Research …, 2020 - Wiley Online Library
After the development of “classical” tricyclic antidepressants and monoamine oxidase
inhibitors, numerous other classes of antidepressant drugs have been introduced onto the …
inhibitors, numerous other classes of antidepressant drugs have been introduced onto the …
Personalized medicine in psychiatry
IK Wium-Andersen, M Vinberg, LV Kessing… - Nordic journal of …, 2017 - Taylor & Francis
Background: Personalized medicine is a model in which a patient's unique clinical, genetic,
and environmental characteristics are the basis for treatment and prevention. Aim, method …
and environmental characteristics are the basis for treatment and prevention. Aim, method …
Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with …
Antidepressants demonstrate modest response rates in the treatment of major depressive
disorder (MDD). Despite previous genome-wide association studies (GWAS) of …
disorder (MDD). Despite previous genome-wide association studies (GWAS) of …
Pharmacokinetic pharmacogenetic prescribing guidelines for antidepressants: a template for psychiatric precision medicine
M Nassan, WT Nicholson, MA Elliott, CRR Vitek… - Mayo Clinic …, 2016 - Elsevier
Antidepressants are commonly prescribed medications in the United States, and there is
increasing interest in individualizing treatment selection for more than 20 US Food and Drug …
increasing interest in individualizing treatment selection for more than 20 US Food and Drug …
Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants
Objectives: More than 40 drugs are available to treat affective disorders. Individual selection
of the optimal drug and dose is required to attain the highest possible efficacy and …
of the optimal drug and dose is required to attain the highest possible efficacy and …